Drug firms facing challenging times due to price control: Cipla.: Drug companies are facing a tough environment due to the government bringing more products under the price control policy as also tightening of registration procedure that has impacted time to market newer products, CiplaBSE 1
1.14 PM Oct 13th
Source:The Hindu BusinessLine - Mumbai, Jan. 31: The Himalaya Drug Company is eyeing the organic segment for personal care products in India with its Botanique brand, a readymade body care range catering to international markets. “The market for organic products is getting big in India
8.55 PM Feb 1st 2013
Source:BBC - Shares in AstraZeneca have fallen 4% after the drugs company announced a drop in sales and said that the tough conditions would continue. Sales in the last three months fell 16% to $7.28bn, as the firm continues to suffer an erosion of business due to the expiry of patents on its drugs
4.18 PM Feb 1st 2013
Source:The Hindu BusinessLine - New Delhi, Jan 30: Drug company Merck Ltd on Wednesday posted a 58.37 per cent rise in net profit at Rs 20.05 crore for the fourth quarter ended December 31, 2012 as against a net profit of Rs 12.66 crore for the same period of previous fiscal. Net sales
4.54 PM Jan 31st 2013
Do not average. FY14 EPS is expected to be at 12. Bulk Drug companies can be valued at a rich PE multiple of 10x. You may average only when price hits below 120. Fundamentally good but valuation-wise, still too expensive. Short to 120, if you can.
3.16 PM Jan 24th 2013
Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.